All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
AACR 2017: Poster 3565/1 – The impact of germline FLT3 mutation on the prognosis of AML patients
At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Monday 3rd April, a poster session titled “Growth Factor and Hormone Receptors as Therapeutic Targets” took place.
During this session, a poster (3561/1) titled “Recurrently detected germline mutation of FLT3 (D358V) associated with prevalence of hematopoietic malignancy and prognosis of AML patients” by Seulki Song and colleagues from the Cancer Research Institute, Seoul, Korea, was on display.
The authors performed a Whole Exome Sequencing (WES) on seventy-six AML patients’ (median age = 46 years) saliva samples.
The key results were:
- Two regions of FLT3 mutations were detected; p.D835V/H and p.D358V
- FLT3 p.D358V mutation frequency was significantly higher in AML patients than in general population; Odds Ratio (OR) = 8.499, P = 9.50E-07
- In normal population (n = 2,504), from the 1,000 Genomes Project, 31% (n = 794) of Asian population carried the FLT3 D358V mutation, OR = 2.26, P = 0.07
- FLT3 p.D358V patients had reduced Overall Survival (OS) compared to patients without FLT3 p.D358V; P = 0.03
In summary, germline mutation in FLT3 is strongly associated with the development of AML. Additionally, germline mutation and somatic mutation of FLT3 is significantly associated with prognosis of AML patients.
References
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?